MPE AGM 2020 webinar series
As part of the educational programme planned to replace the Masterclass included in the MPE Annual General Meeting (AGM) 2020, which was cancelled due to the outbreak of the coronavirus infection, MPE is organising a…
As part of the educational programme planned to replace the Masterclass included in the MPE Annual General Meeting (AGM) 2020, which was cancelled due to the outbreak of the coronavirus infection, MPE is organising a…
Myeloma Patients Europe (MPE) will hold a webinar on myeloma and AL amyloidosis treatment updates on Wednesday 11 March 2020 from 18:30 – 19:30 CET.
Myeloma Patients Europe (MPE) held a webinar yesterday on ASH 2019 myeloma and AL amyloidosis highlights with the aim of reviewing the most recent myeloma findings presented at the annual meeting of the American…
Myeloma Patients Europe will hold a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in Orlando, Florida, USA, in…
The pharmaceutical company Takeda announced that the Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory AL amyloidosis did not meet the first of two primary endpoints. Treatment with ixazomib in combination…
Myeloma Patients Europe held a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in…
Myeloma Patients Europe will hold a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States)…
The annual meeting of the American Society of Haematology (ASH) 2018 starts this week (between 1 and 4 December) in San Diego, California.